The sustainable investor for a changing world

If any good at all is to come of the pandemic, it is already being seen in the rapid and innovative response of the healthcare and medical technology world to a profound and urgent need. Stretching far beyond the development of effective vaccines, this response offers enormous investment potential.  

With much of the world on lockdown (or still dealing with its effects) and social contact discouraged, healthcare provision has taken on a whole new complexion.

Telehealth/telemedicine – the remote diagnosis and treatment of patients unable to visit a clinic or surgery – has proved not only a life-saver but to be highly cost-efficient. According to some reports, video and online medical appointments rose by more than 4 000% in 2020. The global telehealth and telemedicine market is expected to grow from an estimated USD 38.7 billion in 2020 to reach USD 191.7 billion by 2025, not least due to increasing technology adoption in the wake of Covid-19.

A heightened awareness of health issues has increased the use of applications and wearable personal health trackers, reducing appointment pressures on surgeries. Technology in the form of internet and mobile applications has helped governments needing to track and trace the infected.

One technology consulting group claims that the reliance on big data will play a key role in the future of medical technologies, along with software that allows clinicians to sift efficiently through heaps of information. Artificial intelligence, virtual reality and augmented reality will contribute to helping doctors weave their way through an increasingly digital world. The transparency of data offered by the Internet of Medical Things promises to make healthcare an altogether fairer industry.

Medical technology is characterised by constant innovation. In 2019, nearly 14 000 patent applications were filed with the European Patent Office (EPO) in the field of medical technology, more than in any other technical field. In Europe, there are more than 32 000 medical technology companies, employing some 730 000 people.

We believe some of the key investible themes in medical innovation include 

  • The plummeting cost of genome analysis enabling better targeted disease treatment
  • Improved methods of targeted drug delivery
  • Miniaturisation of devices for non-invasive treatments and diagnostics
  • Big data solutions for analysis and telemedicine. 

These approaches could lead to more accessible, cost-effective and coordinated care.

Check out our infographic to see the potential investment opportunities in medical innovation

Also read:

Healthcare – Rocked by the pandemic, the prospects are intact

Spotting the mega trends and the potential winners

Creation and disruption in healthcare (podcast)

Any views expressed here are those of the author as of the date of publication, are based on available information, and are subject to change without notice. Individual portfolio management teams may hold different views and may take different investment decisions for different clients. This document does not constitute investment advice. The value of investments and the income they generate may go down as well as up and it is possible that investors will not recover their initial outlay. Past performance is no guarantee for future returns. Investing in emerging markets, or specialised or restricted sectors is likely to be subject to a higher-than-average volatility due to a high degree of concentration, greater uncertainty because less information is available, there is less liquidity or due to greater sensitivity to changes in market conditions (social, political and economic conditions). Some emerging markets offer less security than the majority of international developed markets. For this reason, services for portfolio transactions, liquidation and conservation on behalf of funds invested in emerging markets may carry greater risk.

Related insights

15:53 MIN
Market weekly – Transforming tech: Innovation and regulation (read or listen)
How can we decarbonise the steel sector?

In the U.S., this material is for Institutional use only – not for public distribution. This material is provided for educational purposes only and is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. References to specific securities, asset classes and financial markets are for illustrative purposes only and are not intended to be and should not be interpreted as recommendations. Reliance upon information in this material is at the sole risk and discretion of the reader. The material was prepared without regard to specific objectives, financial situation or needs of any investor.

These documents and video clips may also include information obtained from affiliated investment management companies within BNP Paribas Asset Management, the brand name of the BNP Paribas group’s asset management services. The documents and video clips are produced for informational purposes only and do not constitute: 1. an offer to buy nor a solicitation to sell, nor shall they form the basis of or be relied upon in connection with any contract or commitment whatsoever or 2. investment advice. Any opinions included in these documents and video clips constitute the judgment of the author/ presenter at the time specified and may be subject to change without notice.

This material may contain “forward-looking” information that is not purely historical in nature. Such information may include, among other things, projections, forecasts, and estimates of yields or returns. No representation is made that any performance presented will be achieved by any funds, or that every assumption made in achieving, calculating or presenting either the forward-looking information or any historical performance information herein has been considered or stated in preparing this material. Any changes to assumptions that may have been made in preparing this material could have a material impact on the investment returns that are presented herein. Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy.

The information and opinions contained in this material are derived from proprietary and nonproprietary sources deemed by BNP PARIBAS ASSET MANAGEMENT USA, Inc. to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy.

The information provided here is neither tax nor legal advice. Investors should speak to their tax professional for specific information regarding their tax situation. Investment involves risk including possible loss of principal. International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation, and the possibility of substantial volatility due to adverse political, economic or other developments. These risks are often heightened for investments in emerging/developing markets or smaller capital markets.


BNP PARIBAS ASSET MANAGEMENT USA, Inc. is registered with the U.S. Securities and Exchange Commission as an investment adviser under the Investment Advisers Act of 1940, as amended. BNP PARIBAS ASSET MANAGEMENT USA, Inc. is a registered trademark of BNP Paribas or its subsidiaries in the United States and elsewhere. All other trademarks are those of their respective owners. © 2021 BNP PARIBAS ASSET MANAGEMENT USA, Inc., All rights reserved.